石静,李悦

• 1:哈尔滨医科大学附属第一临床医学院心内五科

摘要(Abstract)：

加拿大是全球高血压疾病防控最好的国家之一,这与加拿大高血压教育计划(Canadian Hypertension Education Program,CHEP)每年对最新发表的临床试验结果深入解析并制订新一年诊疗推荐计划密不可分。CHEP优点:①更新快,将最新循证证据迅速转化指导临床实践;②更新内容显示清晰,方便阅读,易于掌握。2012~2013 CHEP根据高血压领域最新循证证据,对高血压诊断、评估和治疗推荐进行更新,其管理运行模式对我国高血压防控工作具有重要借鉴意义。

关键词(KeyWords)： 加拿大;高血压;防治

Abstract:

Keywords:

基金项目(Foundation): 辉瑞中国高血压科研基金(WS1932120)

作者(Author): 石静,李悦

参考文献(References)：

• [1]Kearney PM,Whelton M,Reynolds K,et al.Global burden of hypertension:analysis of worldwide data[J].Lancet,2005,365(9455):217-223.
• [2]McAlister FA,Wilkins K,Joffres M,et al.Changes in the rates of awareness,treatment and control of hypertension in Canada over the past two decades[J].CMAJ,2011,183(9):1007-1013.
• [3]Campbell NR,Brant R,Johansen H,et al.Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada[J].Hypertension,2009,53(2):128-134.
• [4]Daskalopoulou SS,Khan NA,Quinn RR,et al.The 2012Canadian hypertension education program recommendations for the management of hypertension:blood pressure measurement,diagnosis,assessment of risk,and therapy[J].Can J Cardiol,2012,28(3):270-287.
• [5]Ohkubo T,Kikuya M,Metoki H,et al.Prognosis of"masked"hypertension and"white coat"hypertension detected by 24-h ambulatory blood pressure monitoring[J].J Am Coll Cardiol,2005,46(2):508-515.
• [6]Warren RE,Marshall T,Padfield PL,et al.Variability of office,24-hour ambulatory,and self-monitored blood pressure measurements[J].Br J Gen Pract,2010,60(578):675-680.
• [7]Bobrie G,Chatellier G,Genes N,et al.Cardiovascular prognosis of"masked hypertension"detected by blood pressure self-measurement in elderly treated hypertensive patients[J].JAMA,2004,291(11):1342-1349.
• [8]Rabi DM,Daskalopoulou SS,Padwal RS,et al.The 2011Canadian Hypertension Education Program recommendations for the management of hypertension:blood pressure measurement,diagnosis,assessment of risk,and therapy[J].Can J Cardiol,2011,27(4):415-433.e1-e2.
• [9]Pitt B,Zannad F,Remme WJ,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators[J].N Engl J Med,1999,341(10):709-717.
• [10]Pitt B,Bakris G,Ruilope LM,et al.Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study(EPHESUS)[J].Circulation,2008,118(16):1643-1650.
• [11]Zannad F,McMurray JJ,Krum H,et al.Eplerenone in patients with systolic heart failure and mild symptoms[J].N Engl J Med,2011,364(1):11-21.
• [12]Jafar TH,Stark PC,Schmid CH,et al.Progression of chronic kidney disease:the role of blood pressure control,proteinuria,and angiotensin-converting enzyme inhibition:a patient-level meta-analysis[J].Ann Intern Med,2003,139(4):244-252.
• [13]Klahr S,Levey AS,Beck GJ,et al.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease.Modification of Diet in Renal Disease Study Group[J].N Engl J Med,1994,330(13):877-884.
• [14]Wright JT Jr,Bakris G,Greene T,et al.Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease:results from the AASK trial[J].JAMA,2002,288(19):2421-2431.
• [15]Ruggenenti P,Perna A,Loriga G,et al.Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease(REIN-2):multicentre,randomised controlled trial[J].Lancet,2005,365(9463):939-946.
• [16]Authors/Task Force Members,Mancia G,Fagard R,et al.2013 ESH/ESC Guidelines for the management of arterial hypertension:The Task Force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].Eur Heart J,2013,34(28):2159-2219.
• [17]Hackam DG,Quinn RR,Ravani P,et al.The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement,diagnosis,assessment of risk,prevention,and treatment of hypertension[J].Can J Cardiol,2013,29(5):528-542.
• [18]Cornelissen VA,Fagard RH,Coeckelberghs E,et al.Impact of resistance training on blood pressure and other cardiovascular risk factors:a meta-analysis of randomized,controlled trials[J].Hypertension,2011,58(5):950-958.
• [19]Gueyffier F,Bulpitt C,Boissel JP,et al.Antihypertensive drugs in very old people:a subgroup meta-analysis of randomised controlled trials[J].Lancet,1999,353(9155):793-796.
• [20]Beckett NS,Peters R,Fletcher AE,et al.Treatment of hypertension in patients 80 years of age or older[J].N Engl J Med,2008,358(18):1887-1898.
• [21]中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93.
• [22]Zhao D,Liu J,Wang W,et al.Epidemiological transition of stroke in China:twenty-one-year observational study from the Sino-MONICA-Beijing Project[J].Stroke,2008,39(6):1668-1674.